Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages ...
In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older. In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or...
Albany Medical Center, Albany, New York, United States
Wake Forest Health Sciences, Winston-Salem, North Carolina, United States
Ramathibodi Hospital, Mahidol University, Ratchathewi, Bangkok, Thailand
Pharma Guide, Cairo, Egypt
MAC Clinical Research Early Phase Unit, Manchester, United Kingdom
UC Davis Medical Center, Sacramento, California, United States
AinShams University, Faculty of medicine, Cairo, Egypt
BC Children's Hospital, Vancouver, British Columbia, Canada
Stanford University, Palo Alto, United States Minor Outlying Islands
Binh Huynh, Ho Chi Minh City, Ho Chi Minh, Vietnam
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.